Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$205.79 USD
-3.83 (-1.83%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $206.04 +0.25 (0.12%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.79 USD
-3.83 (-1.83%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $206.04 +0.25 (0.12%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Zacks News
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
Charles River (CRL) to Support Cure AP-4's Clinical Trials
by Zacks Equity Research
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
by Zacks Equity Research
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
by Zacks Equity Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Aug 3
by Zacks Equity Research
MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
Cano Health, Inc. (CANO) Stock Jumps 17.1%: Will It Continue to Soar?
by Zacks Equity Research
Cano Health, Inc. (CANO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Charles River (CRL) Prospers Internationally Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Why Is Charles River (CRL) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.